| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 100.0% (4/4) | +6.5% | +6.5% | +6.5% |
| 20D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -1.7% | -1.7% | -1.7% |
| 60D | 4Small sample | 100.0% (4/4) | 100.0% (4/4) | +3.6% | +3.6% | +3.6% |
| 120D | 0No data | Awaiting maturity | — | — | — | — |
COMPANY RESEARCH
BIOMERIEUX
BIM.PA · France · Healthcare · Diagnostics & Research
INSIDER SIGNAL
Insider activity score：70.4 / 100
10 insiders · 11 purchase events · €166.76m net purchases
Europe #65 · France #10
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+35.0 / 35
How many distinct insiders bought in the cluster
Purchase size+25.0 / 25
Purchase value relative to company size and liquidity
Role+20.0 / 20
The seniority and relevance of participating insiders
Recency+0.4 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Purchase activity is becoming less recent
- ✓ Broad buyer cluster · 4+ distinct filers
- ✓ Strong insider role · ceo/chair involved
The role contribution uses the inverted role input of the current European model.
Buying concentration
100%
Largest buyer：INSTITUT MERIEUX personne morale liée à Alexandre Mérieux · 167.29m EUR
Gross qualified purchase transaction-line value：167.29m EUR
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Audrey Dauvet | 0 EUR | Aug 31, 2026 |
| CELINE MARTIN ROGER DALBERT | 0 EUR | Aug 31, 2026 |
| INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | 69.9972 EUR | Apr 30, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 9 distinct reported filers
- Peak time window
- 2026-08-31 to 2026-08-31
- Current breadth input
- 1.000 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Audrey Dauvet · 0 EUR · Price 0 EUR · Aug 31, 2026 - 🟢 Eligible purchase
CELINE MARTIN ROGER DALBERT · 0 EUR · Price 0 EUR · Aug 31, 2026 - 🟢 Large eligible purchase
INSTITUT MERIEUX personne morale liée à Alexandre Mérieux · 109.09m EUR · Price 69.9972 EUR · Apr 30, 2026 - 🟡 18 remaining qualified transaction line(s) across 18 disclosure(s)
- 🔴 8 other transaction line(s) are not counted as discretionary-buying evidence; 0 have zero price
Insider vs stock price
3 purchase day(s), 24 purchase line(s) in the 180-day window. 1 sale day(s), 8 sale line(s).
Daily close (EUR)Day with an insider purchaseTwo or more insiders the same dayDay with an insider sale
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-05-05 | 1 | 1,246 +24.6% | too few peers | — |
| 2026-09-02 | 8 | 1,154 +15.4% | too few peers | — |
| 2026-09-03 | 1 | 1,149 +14.9% | too few peers | — |
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (0 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
9 insiders bought on the same day, 31 Aug: 6 Role not classified, 2 CEO / chair, 1 Board member. The share closed at 75.05 that day and at 87.25 most recently (+16.3%). That week 188 companies across Europe disclosed insider purchases, an ordinary week (11 of the last 26). 3 of the buyers also disclosed a sale in the window.
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount. A filing that states no amount gets the smallest dot.
×A sale
A cross is one insider's sales on one day. People sell to pay tax, to cash in share awards or to hold less of one company, so a sale says less than a purchase does. When someone bought and sold on the same day, the cross sits beside the dot. The totals are under “Purchases against sales” below.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 31 Aug, with 9 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
Blue line: this share's price, −3.7% over these six months
The closing price of each day, from 90.60 on 2026-04-21 to 87.25 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −9.2%
Taken from the 104 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −3.7%, the typical one −9.2%, 5.5 points ahead. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 188 companies, number 11 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
Nov
Dec
Jan
Feb
Mar
1Apr
1May
Jun
Jul
9Aug
Sep
Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | CEO / chair | 2 | — | 167.3M EUR | 2026-04-30 | +21.7% | fewer than 5 completed |
| Pierre BOULUD | CEO / chair | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| YASHA MITROTTI VENTURA | CEO / chair | 1 | 1 | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| Francois Lacoste | Board member | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| Audrey Dauvet | Role not classified | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| CELINE MARTIN ROGER DALBERT | Role not classified | 1 | 1 | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| GUILLAUME BOUHOURS | Role not classified | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| Jennifer Zinn | Role not classified | 1 | 1 | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| Pierre Charbonnier | Role not classified | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
| VALERIE LEYLDE | Role not classified | 1 | — | — | 2026-08-31 | +16.3% | fewer than 5 completed |
Purchases against sales
Purchases75%24 line(s) · 10 insider(s)
Sales25%8 line(s) · 3 insider(s)
Shares of the NUMBER of transactions in the 180-day window: a reported value is missing for 20 line(s), or the lines are in more than one currency, so values cannot be added up. Sales include disposals for tax, at option exercise or under a pre-set plan, which say little about an insider's view. The split describes what was disclosed; it is not a signal.
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 1.000 | 35.0 |
| Qualified-buy size | 25% | 1.000 | 25.0 |
| Role informativeness (inverted) | 20% | 0.000 | 0.0 |
| Recency | 10% | 0.038 | 0.4 |
| Buy/sell conviction | 10% | 0.997 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13: no longer on the bull side: large purchases. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (several insiders together, more buyers than usual here, senior executive buying); share price and trading, short sellers were checked and none crosses a bear threshold. No data is held for: company results, company actions.
- The insider purchases themselvesBullseveral insiders together, more buyers than usual here, senior executive buying Bearvalue concentrated in one buyer3 checked, under the threshold · 3 missing
- Share price and trading3 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results2 missing
- Company actionsno data held
Bull case · the buying is informative
- 9 insiders bought on the same day (2026-08-31). Several people reaching the same decision at the same time is hard to put down to one person's circumstances.Record: after 5,401 earlier disclosures like this, the median 60-session excess return was −3.3%, within 1 percentage point of all comparable disclosures (−3.3%).
- No insider bought in the 180 days before this window; 10 have bought in it. The buying is new for this company, not a habit.Record: after 3,134 earlier disclosures like this, the median 60-session excess return was −2.7%, within 1 percentage point of all comparable disclosures (−2.7%).
- The buyers include the CEO or chair, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,797 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.2%).
Bear case · discount it
- INSTITUT MERIEUX personne morale liée à Alexandre Mérieux accounts for 100% of the value bought. The other 9 buyers add names more than money.Record: after 3,396 earlier disclosures like this, the median 60-session excess return was −3.4%, within 1 percentage point of all comparable disclosures (−3.5%).
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- The company's market value is not captured, so the purchases cannot be stated as a share of the business.
- No earnings, margin or cash-flow figures are captured for this company. The latest annual and interim reports are where to check whether the business is improving or deteriorating.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 24 purchase lines mentions a plan, but a bare “Acquisition” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 7
- Bear0 of 10 buyers filed as a person closely associated with a manager. Counted for the bear side from half.
- BearInsiders sold €527k in the same 180 days, 0.31% of the amount bought. Counted for the bear side from 25%.
- EitherThe latest purchase is 47 days old. Bull up to 14 days, bear from 90.
- BearThe share price changed −1.7% over six months (three months +24%, one month +21%) and stands 25% below its 52-week high. Counted for the bear side from a fall of 20%.
- BearOver three months the share price changed +24% and the median of 271 Healthcare companies changed −6.3%: ahead by 30 points. Counted for the bear side from 20 points behind.
- BearThe register of AMF shows no published net short position in this company. Positions under 0.5% are never published, so this does not show that nobody is short. On 2026-09-25 it showed 0.63%: what was published then has since been closed or cut below the threshold.
- BearAbout €15.0M of the stock changes hands on an average day. Counted for the bear side below €500k.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
70.4 / 100
Latest recorded score
↓ -3.4 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)
- Recorded snapshots
- 35
- First snapshot
- 2026-08-26
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Recency-3.4 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 45.5
- 76.1
- 71.4
- 70.7
- 70.4
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-26 | 45.5 |
| 2026-08-27 | 45.5 |
| 2026-08-28 | 45.5 |
| 2026-08-31 | 45.5 |
| 2026-09-01 | 45.5 |
| 2026-09-02 | 45.5 |
| 2026-09-03 | 78.1 |
| 2026-09-04 | 77.5 |
| 2026-09-07 | 76.1 |
| 2026-09-08 | 75.7 |
| 2026-09-09 | 75.3 |
| 2026-09-10 | 75.0 |
| 2026-09-11 | 74.6 |
| 2026-09-14 | 73.8 |
| 2026-09-23 | 72.0 |
| 2026-09-24 | 71.9 |
| 2026-09-25 | 71.7 |
| 2026-09-28 | 71.4 |
| 2026-09-29 | 71.3 |
| 2026-09-30 | 71.2 |
| 2026-10-01 | 71.1 |
| 2026-10-02 | 71.1 |
| 2026-10-03 | 71.1 |
| 2026-10-04 | 71.1 |
| 2026-10-05 | 70.9 |
| 2026-10-06 | 70.8 |
| 2026-10-07 | 70.7 |
| 2026-10-08 | 70.7 |
| 2026-10-09 | 70.6 |
| 2026-10-12 | 70.5 |
| 2026-10-13 | 70.5 |
| 2026-10-14 | 70.4 |
| 2026-10-15 | 70.4 |
| 2026-10-16 | 70.4 |
| 2026-10-18 | 70.4 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − CAC 40 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -2.9% | -2.9% | -3.7% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | -0.0% | -0.0% | -6.7% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -12.2% | -12.2% | -12.2% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -20.8% | -20.8% | -20.8% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -2.7% | -2.7% | -3.7% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | +1.7% | +1.7% | -3.3% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -10.1% | -10.1% | -10.1% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -23.3% | -23.3% | -23.3% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 26.2%
- Beta
- —
- Avg daily volume
- €8.6M
VALUATION
- Market cap
- —
- P/E
- —
FUNDAMENTALS
- Profit margin
- 9.8%
- ROE
- 9.7%
- Industry
- —
Prices to 18 Oct 2026: price cache (Eulerpool). From the company's annual report ↗, fiscal year ended 31 Dec 2025: Profit margin, ROE. It does not affect the insider score or rank.
Disclosed net short positions
The AMF register, read 18 Oct 2026, publishes no net short position of 0.5% or more in this issuer. Positions below 0.5% are never published, so this is not evidence that nobody is short.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
Insiders paid 70.67 EUR a share on average (4 purchase lines, 1 buyer, 2026-04-30 – 2026-05-04). The close on 2026-10-16 was 23.5% above that price.
The latest purchase (2026-05-04) was at 71.96 EUR; the close was 21.2% above that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored. 20 more purchase lines could not be compared with the share price and are left out.
Buying size vs market trading
0.00% · of estimated traded value in the same period
2026-09-21 – 2026-10-16 · 20 recorded trading sessions
- Disclosed qualifying purchases
- 0 EUR
- Estimated market traded value
- 299,964,363 EUR
Market-data coverage: 511 verified sessions · Latest session: 2026-10-16 · Ratio status: Available
Recent and largest purchase events / preceding 60-session ADTV
- Aug 31 · Audrey Dauvet · Directrice Exécutive Affaires juridiques, Conformité et Affaires Publiques— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · CELINE MARTIN ROGER DALBERT · Directrice Exécutive Recherche & Développement— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · Francois Lacoste · Membre du Conseil— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · GUILLAUME BOUHOURS · Directeur Exécutif Finances, Achats et Systèmes d'Information— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · Jennifer Zinn · Directrice Exécutive des Opérations Cliniques— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · Pierre BOULUD · Directeur Général— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 31 · Pierre Charbonnier · Directeur Exécutif Qualité Globale, Manufacturing et Supply Chain— · —Some purchases lack a valid value; aggregate ratio withheld.
- Apr 30 · INSTITUT MERIEUX personne morale liée à Alexandre Mérieux · Président du Conseil d'administration109,089,936 EUR · 785.76%13,883,415 EUR ADTV
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
The filing records held for this company carry no link to the original notice.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
24 qualifying purchase disclosure(s) · 24 transaction line(s)
Aug 31, 2026Acquisition
YASHA MITROTTI VENTURA · Executive Vice President Industrial Applications
Actions gratuites · 4200.0000 shares × 0.0000 EUR · —
Aug 31, 2026Acquisition
YASHA MITROTTI VENTURA · Executive Vice President Industrial Applications
Actions gratuites · 703.0000 shares × 0.0000 EUR · —
Aug 31, 2026Acquisition
Jennifer Zinn · Directrice Exécutive des Opérations Cliniques
Actions gratuites · 1088.0000 shares × 0.0000 EUR · —
Unfold all 21 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 6500.0000 | — |
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 2134.0000 | — |
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 357.0000 | — |
| 2026-08-31 | 2026-09-02 | GUILLAUME BOUHOURS | Directeur Exécutif Finances, Achats et Systèmes d'Information | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 737.0000 | — |
| 2026-08-31 | 2026-09-02 | GUILLAUME BOUHOURS | Directeur Exécutif Finances, Achats et Systèmes d'Information | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 4400.0000 | — |
| 2026-08-31 | 2026-09-02 | CELINE MARTIN ROGER DALBERT | Directrice Exécutive Recherche & Développement | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 201.0000 | — |
| 2026-08-31 | 2026-09-02 | CELINE MARTIN ROGER DALBERT | Directrice Exécutive Recherche & Développement | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 1203.0000 | — |
| 2026-08-31 | 2026-09-02 | Pierre BOULUD | Directeur Général | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 9200.0000 | — |
| 2026-08-31 | 2026-09-02 | Pierre BOULUD | Directeur Général | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 1541.0000 | — |
| 2026-08-31 | 2026-09-02 | VALERIE LEYLDE | Directrice Exécutive Ressources Humaines, Communication & RSE | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 552.0000 | — |
| 2026-08-31 | 2026-09-02 | VALERIE LEYLDE | Directrice Exécutive Ressources Humaines, Communication & RSE | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 3300.0000 | — |
| 2026-08-31 | 2026-09-02 | Pierre Charbonnier | Directeur Exécutif Qualité Globale, Manufacturing et Supply Chain | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 4300.0000 | — |
| 2026-08-31 | 2026-09-02 | Pierre Charbonnier | Directeur Exécutif Qualité Globale, Manufacturing et Supply Chain | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 720.0000 | — |
| 2026-08-31 | 2026-09-02 | Audrey Dauvet | Directrice Exécutive Affaires juridiques, Conformité et Affaires Publiques | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 3000.0000 | — |
| 2026-08-31 | 2026-09-02 | Audrey Dauvet | Directrice Exécutive Affaires juridiques, Conformité et Affaires Publiques | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 502.0000 | — |
| 2026-08-31 | 2026-09-03 | Francois Lacoste | Membre du Conseil | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 3600.0000 | — |
| 2026-08-31 | 2026-09-03 | Francois Lacoste | Membre du Conseil | Acquisition | Actions gratuites | 0.0000 EUR | EUR | 603.0000 | — |
| 2026-05-04 | 2026-05-05 | INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | Président du Conseil d'administration | Acquisition | Action | 71.9640 EUR | EUR | 404367.0000 | — |
| 2026-05-04 | 2026-05-05 | INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | Président du Conseil d'administration | Acquisition | Action | 71.9640 EUR | EUR | 404367.0000 | — |
| 2026-04-30 | 2026-05-05 | INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | Président du Conseil d'administration | Acquisition | Action | 69.9972 EUR | EUR | 779245.0000 | — |
| 2026-04-30 | 2026-05-05 | INSTITUT MERIEUX personne morale liée à Alexandre Mérieux | Président du Conseil d'administration | Acquisition | Action | 69.9972 EUR | EUR | 779245.0000 | — |
Showing 24 of 24 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 8 other transaction(s)
Aug 31, 2026Cession
YASHA MITROTTI VENTURA · Executive Vice President Industrial Applications
actions gratuites · 2034.0000 shares × 74.9304 EUR · —
Aug 31, 2026Cession
YASHA MITROTTI VENTURA · Executive Vice President Industrial Applications
actions gratuites · 341.0000 shares × 74.9304 EUR · —
Aug 31, 2026Cession
Jennifer Zinn · Directrice Exécutive des Opérations Cliniques
actions gratuites · 2675.0000 shares × 74.9304 EUR · —
Unfold all 5 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Cession | actions gratuites | 74.9304 EUR | EUR | 448.0000 | — |
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Cession | Actions gratuites | 74.9304 EUR | EUR | 147.0000 | — |
| 2026-08-31 | 2026-09-02 | Jennifer Zinn | Directrice Exécutive des Opérations Cliniques | Cession | Actions gratuites | 74.9304 EUR | EUR | 879.0000 | — |
| 2026-08-31 | 2026-09-02 | CELINE MARTIN ROGER DALBERT | Directrice Exécutive Recherche & Développement | Cession | Actions gratuites | 74.9304 EUR | EUR | 72.0000 | — |
| 2026-08-31 | 2026-09-02 | CELINE MARTIN ROGER DALBERT | Directrice Exécutive Recherche & Développement | Cession | Actions gratuites | 74.9304 EUR | EUR | 431.0000 | — |
Showing 8 of 8 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- BIM.PA
- ISIN
- FR0013280286
- Sector
- Healthcare
- Industry
- Diagnostics & Research
Company logos by Parqet